Erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis (production of red blood cells). These erythropoietin (EPO) drugs are used for treatment of chemotherapy-induced anemia; anemia is a common side-effect occurring due to chemotherapy of End Stage Renal Diseases (ESRD), cancer and HIV.By alliedmarketresearch
Report Overview Research Beam adds a report titled “Global Erythropoietin Drugs Market (Products, Applications and Geography) 2013-2020” that provides detailed information of the Global Erythropoietin Drugs Market. The report is an excellent piece of study for investors who are looking towards the market. Erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis (production of red blood cells). These erythropoietin (EPO) drugs are used for treatment of chemotherapy-induced anemia; anemia is a common side-effect occurring due to chemotherapy of End Stage Renal Diseases (ESRD), cancer and HIV. Improved recombinant DNA technology has led to development of synthetic forms of erythropoietin such as epoetin alfa, epoetin beta, darbepoetin alfa, epoetin omega, and epoetin delta among the others. The global EPO drugs market is thus driven by increasing number of patients suffering from anemic condition induced due to cancer, HIV and ESRD treatment; favorable reimbursements and increasing commercialization of EPO biosimilars. The global EPO drugs market would reach $11.9 billion by 2020, registering CAGR of 9.7% during 2014-2020. Get Full Details On: http://www.researchbeam.com/erythropoietin-marketBy MarkLesnar
“Erythropoietin” is a glycoprotein hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis (production of red blood cells). For More Details : http://goo.gl/i4dmlsBy addyparker2350
Erythropoietin Drugs Market is Expected to Reach $11.9 Billion by 2020. Visit at: https://www.alliedmarketresearch.com/erythropoietin-market\n\nA new report by Allied Market Research titled, \"Global Erythropoietin (EPO) Drugs Market (Type, Application and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013-2020\", forecasts the Global EPO market to reach $11.9 billion by 2020, with promising CAGR of 9.7% from 2014 to 2020. Darbepoetin alfa is fastest growing drug class at a CAGR of 12.9% during the forecast period, owing to its high potency and minimal side-effects.\nBy bethzhurst
MarketReportsOnline.com adds \"Global Erythropoietin (EPO) Market with Focus on Asia: Industry Analysis & Outlook (2016-2020)\" report to its research store.\n\nErythropoietin is a substance produced by the kidney that leads to the formation of red blood cells in the bone marrow. It is a glycoprotein hormone which regulates erythropoiesis (Red Blood Cell production). For erythrocyte precursors present in the bone marrow, EPO acts as a cytokine. Commonly referred to as hematopoietin or hemopoietin, erythropoietin is also known to have other biological functions, such as involvement in the wound healing cycle and brain’s response to neuronal injury.\n\nComplete report available at http://www.marketreportsonline.com/508284.html.\n\nPeople suffering from End Stage Renal Disease (ESRD), HIV or undergoing chemotherapy are not able to produce enough EPO on their own and thus, are administered with synthetic or recombinant erythropoietin which has the similar sequence of amino acids. Recombinant erythropoietin is a kind of therapeutic agent devised using DNA technology.\n\nOn the bases of their molecular structure, EPO drugs can be divided into five categories: epoetin-alfa, epoetin-beta, epoetin-omega, epoetin-delta and darbepoetin-alfa. Among these epoetin-alfa and darbepoetin-alfa are most commonly prescribed EPO drugs.\n\nThe global EPO drugs market is expected to experience negative growth rate, primarily due to expiry of patents of two most common EPO drugs, epoetin-alfa and darbepoetin-alfa, allowing the entry of biosimilars; posing a serious threat to EPO drugs market. However, the Asia-Pacific region is expected to experience boom period majorly due to improving disposable income and better government medical reimbursement policies.\n\nThe report “Global Erythropoietin (EPO) Market with Focus on Asia: Industry Analysis & Outlook (2016-2020)” analyzes the development of this market, with focus on the US and Asia-Pacific markets. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Johnson & Johnson, Amgen, Roche and Teva Pharmaceutical Industries Limited are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global EPO market along with the study of the regional markets.\n\nOrder a copy of this “Global Erythropoietin (EPO) Market with Focus on Asia: Industry Analysis & Outlook (2016-2020)”research report at USD 900 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=508284.\n\nAbout Us:\nMarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.\n\nContact Us:\nRitesh Tiwari\n2nd Floor, Metropole,\nNext to Inox Theatre,\nBund Garden Road,\nPune - 411001.\nMaharashtra, India.\nTel: 1 888 391 5441\nE-mail: firstname.lastname@example.orgBy calebjackson
View Global epo drugs market PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Global epo drugs market PowerPoint presentations. You can view or download Global epo drugs market presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.
Global EPO Biomarkers Market, Size, Share, Market Intelligence, Company Profiles, Market Trends, Strategy, Analysis, Forecast 2018-2023
Epo Biomarkers Market, by Biomarker Type (Recombinant Human Erythropoietin, Erythropoietin Alfa, Erythropoietin Beta, Erythropoietin Zeta, Erythropoietin Theta, and Darbepoietin Alfa), by Application (End-stage Renal Disorder, Cancer, Rheumatoid Arthritis, AIDS, Myelodysplastic Syndrome, Neurology, Hematology, and Others), by End User (Diagnostic Centers, Hospitals, and Ambulatory Care and Surgical Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027\n
Global Antiulcerant Drugs Market is expected to grow at a CAGR of 2.6% from 2017 to 2025. The report highlights the key trends, market outlook and the global scenario of the Global Antiulcerant Drugs Market.
\nGlobal Veterinary Drugs Market was valued at USD xx million in 2018 and is expected to reach at USD xx million by 2026 at a CAGR of xx% over forecast period 2019-2026.
The report analyses the antiretroviral market, By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India, and South Africa) for the historical period of 2013-2017 and the forecast period of 2018-2023. This report also includes drug sales forecast for some antiretroviral drugs. Request free Sample of this Report @: http:\/\/azothanalytics.com\/report\/healthcare-pharma\/global-antiretroviral-drugs-market-analysis-by-drug-type-multi-class-drugs-combination-drugs-nrti-nnrti-protease-inhibitors-by-region-by-country-drug-forecast-2019-edition-opportunities-and-forecast-2013-2023-r32196Visit us: http:\/\/azothanalytics.com\/research\/healthcare-pharma-c1
Global Gynecology Drugs Market was valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2026, at a 7.2% CAGR of around XX% during a forecast period.\n
Global Immunotherapy Drugs Market was valued US$ 110.5 Mn in 2016 and expected to reach US$ 304.96 Mn by 2024 at CAGR of 13.53% (Detailed analysis of the market CAGR is provided in the report).